Pramipexole is a non-ergoline dopamine agonist used primarily for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS). It acts by selectively stimulating dopamine D2, D3, and D4 receptors in the brain, compensating for the dopamine deficiency characteristic of Parkinson's disease. In the Indian context, it is a widely prescribed, cost-effective alternative to other dopamine agonists.
Adult: Parkinson's: Start 0.125 mg TID. Titrate weekly by 0.125 mg TID to effective dose (max 1.5 mg TID). Usual maintenance: 0.5-1.5 mg TID. RLS: Start 0.125 mg once daily, 2-3 hours before bedtime. Titrate every 4-7 days to 0.25 mg, then to 0.5 mg if needed. Max for RLS: 0.5 mg daily.
Note: Administer orally with or without food. For Parkinson's, doses are typically divided three times daily. For RLS, take as a single dose 2-3 hours before bedtime. Tablet can be split. Do not crush or chew extended-release formulations (if applicable, though 0.5mg is typically immediate-release).
Pramipexole exerts its therapeutic effects by directly stimulating postsynaptic dopamine receptors in the striatum. It has high specificity for D2 subfamily receptors (D2, D3, and D4), with a 5- to 7-fold higher affinity for D3 receptors. This stimulation compensates for the depleted dopamine levels in Parkinson's disease. In RLS, its mechanism is believed to involve modulation of dopaminergic pathways in the spinal cord.
Pregnancy: Pregnancy Category C. Animal studies showed adverse effects. No adequate, well-controlled studies in pregnant women. Use only if potential benefit justifies potential fetal risk.
Driving: Patients must be warned about the potential for somnolence and sudden onset of sleep ('sleep attacks') during activities like driving or operating machinery. They should not drive until they have gained sufficient experience with the drug's effects.
| Levodopa/Carbidopa | Increased risk of dyskinesias, hallucinations, and orthostatic hypotension. May allow reduction of levodopa dose. | Major |
| Antipsychotics (e.g., Haloperidol, Risperidone) | Antagonism of dopaminergic effect, reducing efficacy of pramipexole. | Major |
| Metoclopramide, Domperidone | Domperidone may antagonize effect. Metoclopramide is contraindicated as it crosses BBB. | Major |
| Antihypertensives | Additive hypotensive effect. | Moderate |
| Cimetidine | Reduces renal clearance of pramipexole, increasing AUC by ~50%. Dose adjustment may be needed. | Moderate |
| CYP1A2 inhibitors (e.g., Ciprofloxacin, Fluvoxamine) | Theoretical increase in pramipexole levels (minor pathway). Clinical significance likely low. | Minor |
| Sedatives (Benzodiazepines, Opioids, Alcohol) | Additive sedative effects, increasing risk of somnolence and sleep attacks. | Moderate |